NCT01201850View on ClinicalTrials.gov

The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors

NATerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 28, 2010

Primary Completion Date

August 4, 2016

Study Completion Date

August 4, 2016

Conditions
Radiation Necrosis
Interventions
DRUG

Bevacizumab (Avastin®)

Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. An MRI will be done after the first cycle (3 doses/ 6weeks) and then again at the end of therapy.

Trial Locations (1)

80045

Children's Hospital Colorado, Aurora

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Colorado, Denver

OTHER